Case Western Reserve University/Cleveland Clinic CTSA (UL1 RR-024989)

Oct. 13, 2009

$983,229 has been awarded to Dr. Chance and the Case Center for Proteomics and Bioinformatics in response to Dr. Chance's submission of a Recovery Act Administrative Supplement Request in response to NCRR ARRA Supplements to Advance Translational (Tl & T2) Research- Translational. The administrative supplement was requested under the parent grant entitled "Case Western Reserve University/Cleveland Clinic CTSA". (UL1 RR-024989, PI: Dr. Pamela B. Davis).

The supplement to the Center for Translational Science Award (UL1-RR024989) based at Case Western Reserve University, and involving University Hospitals, Cleveland Clinic, and Metro Health Center, will Advance Translational (T1& T2) Research through the development, testing, and implementation of a set of System Medicine Data Analysis (SMDA) pipelines to integrate .omics data and enhance clinical and translational research activities of CTSA investigators. The Translational Technologies Core of the CTSA, in the two years of funding available so far, has been very successful in the development and implementation of information technology systems to collect and organize .omics data generated by various cores, through its Integrated Multi-Modality Information Management System (MIMI). The next step is to provide investigators with user-friendly tools to integrate this data with biological and clinical information pertinent to their research goals. Through collaborations between faculty in physiology, genetics, bioinformatics, proteomics, biomedical engineering, and computer science we will integrate .omics data in the context of, and driven by, the topology of protein-protein interaction networks to provide a functional framework for integrating different types of data. The resulting SMDA tools for disease analysis will be web-based, open source, scalable, and will ultimately serve clinical and translational researchers in Cleveland in many areas of disease research, especially those that involve complex phenotypes. It will be made available to the local community through workshops and individual training of CTSA investigators and will be disseminated to the wider CTSA community through the coordination and outreach efforts of the Translational Technologies Key Functions Committee (TTKFC), of which the Project Coordinator, Dr. Chance, is a member.

Relevance: Identification of biomarkers and therapeutic targets of disease is one of the most important goals of medical research. With these targets we can identify disease, monitor its progression, and fight its effects. The supplement will provide computer models and resources to increase the speed at which we sift through the possible targets to identify "high-value" candidates suitable for focused translation to medical practice.